Hi Nick,
I guess everybody who tried to build a disease progression model had
already read your publications. :)
You are right. CFB is really not a good end point to understand disease
progression.
The reasons I chose CFB: 1) The only objective is to determine when is
steady state. 2) The data is extremely limited. Several publications were
collected cross different drugs, doses, and population. I touched Worst
Modelling Practice <a joke> But anyway, the raw data (papers) spoke
something for future trial design.
When I have an acceptable data set, I definetly will follow your
suggestions.
Best regards,
Guangli
Received on Thu Mar 04 2010 - 02:29:10 EST
This archive was generated by hypermail 2.2.0 : Thu Mar 04 2010 - 03:02:44 EST